PremiumRatingsImmunityBio’s Strategic Growth and Innovation in Immunotherapy: A Buy Recommendation ImmunityBio completes multiple submissions to the FDA including sBLA ImmunityBio Secures $75 Million in Direct Offering PremiumThe FlyImmunityBio initiated with a Buy at H.C. Wainwright ImmunityBio’s Sales Surge Amid Strategic Advances ImmunityBio reports Q4 EPS (9c), consensus (13c) PremiumThe FlyFDA authorizes ImmunityBio to provide rBCG to urologists amid shortages ImmunityBio announces UK acceptance of Anktiva marketing application ImmunityBio Approves 2024 Executive Bonuses and New Incentives 
